The THIO-104 study listing is live, along with questions about funding the trial.
ApexOnco Front Page
Recent articles
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
